Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Cancer immunology

CAR macrophages on a fast track to solid tumor therapy

Nature Immunology volume 25, pages 11–12 (2024)Cite this article

Subjects

Expressing chimeric antigen receptors (CARs) in macrophages has led to promising results in preclinical and clinical work. Now, induced pluripotent stem cells have been combined with a second-generation CAR to achieve macrophage rewiring and to broaden the applicability of the approach to solid malignancies.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Human iPS cell-derived macrophages with a second-generation CAR.

References

  1. Xiang, X., Wang, J., Lu, D. & Xu, X. Signal Transduct. Target Ther. 6, 75 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  2. Lei, A. et al. Nat. Immunol. https://doi.org/10.1038/s41590-023-01687-8 (2023).

    Article  PubMed  Google Scholar 

  3. Zhang, L. et al. J. Hematol. Oncol. 13, 153 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Morrissey, M. A. et al. eLife 7, e36688 (2018).

    Article  PubMed  PubMed Central  Google Scholar 

  5. Klichinsky, M. et al. Nat. Biotechnol. 38, 947–953 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Wang, X. et al. Nat. Commun. 14, 5778 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Ackermann, M. et al. Nat. Protoc. 17, 513–539 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Ackermann, M. et al. Nat. Commun. 9, 5088 (2018).

    Article  PubMed  PubMed Central  Google Scholar 

  9. Gutbier, S. et al. Int. J. Mol. Sci. 21, 4808 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Kerzel, T. et al. Cancer Cell https://doi.org/10.1016/j.cell.2023.09.014 (2023).

    Article  PubMed  Google Scholar 

  11. Jin, H., Wang, L. & Bernards, R. Nat. Rev. Drug Discov. 22, 213–234 (2023).

    Article  CAS  PubMed  Google Scholar 

  12. Pierini, S., Gabbasov, R., Gabitova, L., Ohtani, Y. & Klichinsky, M. J. Immunother. Cancer https://doi.org/10.1136/jitc-2020-SITC2020.0132 (2020).

Download references

Acknowledgements

N.L. is supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany’s Excellence Strategy (EXC 2155; project number 390874280 and DFG support LA 3680/9-1); the REBIRTH Research Center for Translational Regenerative Medicine ‘Förderung aus Mitteln des Niedersächsischen Vorab’ (grant ZN3340); the European Research Council (ERC) under the European Union (EU)’s Horizon 2020 research and innovation program (grant agreement 852178); and the EU (grant agreement 101100859). The views and opinions expressed are, however, those of the authors only and do not necessarily reflect those of the EU or the ERC. Neither the EU nor the granting authority can be held responsible for them.

Author information

Authors and Affiliations

  1. Department of Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany

    Shifaa M. Abdin, Daniela Paasch & Nico Lachmann

  2. Center for Translational and Regenerative Medicine, Hannover Medical School, Hannover, Germany

    Shifaa M. Abdin, Daniela Paasch & Nico Lachmann

  3. RESIST, Cluster of Excellence, Hannover Medical School, Hannover, Germany

    Nico Lachmann

  4. Biomedical Research in End Stage and Obstructive Lung Disease Hannover (BREATH), German Center for Lung Research (DZL), Hannover, Germany

    Nico Lachmann

  5. Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), Hannover, Germany

    Nico Lachmann

Authors
  1. Shifaa M. Abdin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniela Paasch
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nico Lachmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nico Lachmann.

Ethics declarations

Competing interests

N.L. declares a patent application on the generation of human iPS cell-derived macrophages (IP PCT/EP2018/061574). The other authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Abdin, S.M., Paasch, D. & Lachmann, N. CAR macrophages on a fast track to solid tumor therapy. Nat Immunol 25, 11–12 (2024). https://doi.org/10.1038/s41590-023-01696-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41590-023-01696-7

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing